192 related articles for article (PubMed ID: 15156182)
1. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
Mitani K
Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of blastic crisis in chronic myelocytic leukemia.
Mitani K
Leukemia; 1997 Apr; 11 Suppl 3():503-5. PubMed ID: 9209439
[TBL] [Abstract][Full Text] [Related]
3. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP.
Izutsu K; Kurokawa M; Imai Y; Ichikawa M; Asai T; Maki K; Mitani K; Hirai H
Oncogene; 2002 Apr; 21(17):2695-703. PubMed ID: 11965542
[TBL] [Abstract][Full Text] [Related]
4. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence.
Kurokawa M; Ogawa S; Tanaka T; Mitani K; Yazaki Y; Witte ON; Hirai H
Oncogene; 1995 Sep; 11(5):833-40. PubMed ID: 7675444
[TBL] [Abstract][Full Text] [Related]
5. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
Kurokawa M; Mitani K; Imai Y; Ogawa S; Yazaki Y; Hirai H
Blood; 1998 Dec; 92(11):4003-12. PubMed ID: 9834202
[TBL] [Abstract][Full Text] [Related]
6. [Leukemogenesis by the AML1/EVI-1 chimeric protein].
Mitani K; Hirai H
Tanpakushitsu Kakusan Koso; 2000 Jan; 45(1):33-9. PubMed ID: 10643333
[No Abstract] [Full Text] [Related]
7. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
Tanaka T; Mitani K; Kurokawa M; Ogawa S; Tanaka K; Nishida J; Yazaki Y; Shibata Y; Hirai H
Mol Cell Biol; 1995 May; 15(5):2383-92. PubMed ID: 7739522
[TBL] [Abstract][Full Text] [Related]
8. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP.
Nitta E; Izutsu K; Yamaguchi Y; Imai Y; Ogawa S; Chiba S; Kurokawa M; Hirai H
Oncogene; 2005 Sep; 24(40):6165-73. PubMed ID: 15897867
[TBL] [Abstract][Full Text] [Related]
9. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
10. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
11. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.
Kurokawa M; Mitani K; Yamagata T; Takahashi T; Izutsu K; Ogawa S; Moriguchi T; Nishida E; Yazaki Y; Hirai H
EMBO J; 2000 Jun; 19(12):2958-68. PubMed ID: 10856240
[TBL] [Abstract][Full Text] [Related]
12. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
Mitani K; Ogawa S; Tanaka T; Miyoshi H; Kurokawa M; Mano H; Yazaki Y; Ohki M; Hirai H
EMBO J; 1994 Feb; 13(3):504-10. PubMed ID: 8313895
[TBL] [Abstract][Full Text] [Related]
13. AML1-Evi-1 specifically transforms hematopoietic stem cells through fusion of the entire Evi-1 sequence to AML1.
Takeshita M; Ichikawa M; Nitta E; Goyama S; Asai T; Ogawa S; Chiba S; Kurokawa M
Leukemia; 2008 Jun; 22(6):1241-9. PubMed ID: 18337762
[TBL] [Abstract][Full Text] [Related]
14. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.
Kurokawa M; Mitani K; Irie K; Matsuyama T; Takahashi T; Chiba S; Yazaki Y; Matsumoto K; Hirai H
Nature; 1998 Jul; 394(6688):92-6. PubMed ID: 9665135
[TBL] [Abstract][Full Text] [Related]
15. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
16. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
17. TEL/AML1 shows dominant-negative effects over TEL as well as AML1.
Gunji H; Waga K; Nakamura F; Maki K; Sasaki K; Nakamura Y; Mitani K
Biochem Biophys Res Commun; 2004 Sep; 322(2):623-30. PubMed ID: 15325275
[TBL] [Abstract][Full Text] [Related]
18. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
19. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21).
Kozu T; Fukuyama T; Yamami T; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2005 May; 43(1):45-53. PubMed ID: 15723339
[TBL] [Abstract][Full Text] [Related]
20. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
